[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility-of-uterine-origin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility-of-uterine-origin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100480619","platelet-rich-plasma-for-insufficient-endometrium-100480619",false,"NCT05538338","Platelet Rich Plasma for Insufficient Endometrium","Intrauterine Platelet Rich Plasma (PRP) Infusion for Endometrial Insufficiency: A Prospective, Double-Blind, Placebo-Controlled Randomized Controlled Trial","PIER","Inclusion Criteria:\n\n* Patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical pregnancy (visualization of intrauterine gestational sac on ultrasound or a cancelled embryo transfer cycle due to inadequate endometrial thickness\n* Patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo transfer cycles.\n\nExclusion Criteria:\n\n* Fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles.\n* Most recent unsuccessful embryo transfer prior to January 1, 2017.\n* Mullerian anomalies, excluding arcuate uterus\n* Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery\n* Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.\n* Failure of patient to agree to enrollment in study with written consent.\n* Concurrent pregnancy\n* Anticoagulation use for which plasma infusion is contraindicated\n* History of thrombosis\n* Thrombophilia either inherited or acquired\n* Concomitant use of adjunctive therapies for proliferation. These must be discontinued upon enrollment.\n* Embryo planned to be used for transfer generated from surgically obtained sperm due to a diagnosis of non-obstructive azoospermia\n* Recurrent\u002Fpersistent endometrial fluid in prior cycles","FEMALE","18 Years","45 Years",{"count":21,"type":22},62,"ESTIMATED","INTERVENTIONAL",[25],"NA","To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.",[28],"Infertility of Uterine Origin","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":33},"2022-10-15",{"date":37,"type":22},"2027-12",{"name":39,"class":40},"Reproductive Medicine Associates of New Jersey","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100459473","uterine-transplant-for-women-with-absolute-uterine-factor-infertility-aufi-100459473","NCT05263076","Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)","Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Factor Infertility","RECIPIENT INCLUSION CRITERIA\n\n1. Women who are diagnosed with Absolute Uterine Factor Infertility (AUFI) and who have at least one functioning ovary.\n2. Women of childbearing age (20-40 years old) who are biologically female (XX karyotype).\n3. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present.\n4. Subjects will have negative testing for Gonorrhea Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD\u002Finfection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. She will then become eligible for transplant. If a subject develops an STD\u002Finfection after transplant\u002Fduring pregnancy she will be treated appropriately. Prior to the embryo transfer the patient will be tested and treated if necessary. Any patient with an active STD\u002Finfection will be ineligible for any elective procedure until she is tested and treated appropriately.)\n5. Subjects who are HSV-2 negative or who have a history of HSV-2 with no current symptoms. Subjects may require preventative maintenance per study doctor discretion.\n6. Subjects have received counseling regarding all fertility options and alternatives to uterine transplant such as adoption or surrogate pregnancy.\n7. Subjects are willing to undergo in-vitro fertilization to obtain the necessary 4 viable embryos required for eligibility for transplant if they have not already banked 4 viable embryos.\n8. Subjects have been evaluated by a fertility specialist and determined to have good ovarian reserve and reproductive potential.\n9. Subjects must agree that in the event of withdrawal from the study while the transplanted uterus is in place, unless she is enrolled in an equivalent uterine transplant program, she will be required to undergo a hysterectomy for her own safety.\n10. Subject meets psychological recipient criteria.\n11. Subject must be willing to complete questionnaires about their infant's growth and development and return them to the study team.\n\nRECIPIENT EXCLUSION CRITERIA\n\n1. Subject with Diabetes Mellitus Type I and II by medical history or elevated hemoglobin A1c blood test.\n2. Subject has known hypersensitivity to Tacrolimus, Thymoglobulin or Everolimus.\n3. Subject with a diagnosis of hypertension, or any other significant medical condition that makes this procedure unsafe or is a contraindication to surgery or anesthesia.\n4. Subject who has a history of solid organ or bone marrow transplant, per investigator's discretion.\n5. Subject who has a history of cancer, per investigator's discretion.\n6. Subject with a body mass index \\>30.\n7. Subject with an active infection including candida and\u002For bacterial vaginosis.\n8. Subject who is seropositive for HIV, HBV, HCV.\n9. Subject with technical obstacles as per anatomical malformations, which pose a high surgical risk in the judgment of the investigator.\n10. Subject unwilling or unable to comply with study requirements.\n11. Subject unable to undergo in-vitro fertilization or not cleared for transplant.\n12. Subject who has smoked within the last 6 months.\n13. Subject who has alcohol or drug abuse within 12 months of screening.\n14. Subject with any pre-existing clinical or medical conditions that would put the subject at an increased risk. Of note, for Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, the investigators will favor Type 1 variants as Type 2 is associated with skeletal\u002Fspinal and renal anomalies, making them higher risk candidates.\n\nDONOR INCLUSION CRITERIA\n\n1. Women must be between 25-65 years of age. If a subject is less than 40 years old she must be certain that she does not wish to carry more children, and she will attest to this decision.\n2. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present.\n3. Subjects will have negative testing for Gonorrhea, Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD\u002Finfection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. Any patient with an active STD\u002Finfection will be ineligible for any elective procedure until she is tested and treated appropriately.)\n4. Subjects who are HSV-2 negative, or have a history of HSV-2 but with no current symptoms. Subjects may require preventative maintenance per study doctor discretion.\n5. Subjects will have a normal uterus on sonogram and CT.\n6. Subjects will have normal psychological donor criteria (if living).\n7. Subjects will have had at least one prior full term live birth.\n\nDONOR EXCLUSION CRITERIA\n\n1. Donor over the age of 65.\n2. Body mass index \\>30.\n3. Subject with an active infection including candida and\u002For bacterial vaginosis.\n4. Subject who is seropositive for HIV, HBV, HCV\n5. Subject who has had cancer in the last five years.\n6. Subject with any pre-existing clinical or medical condition that would place the subject at an increased risk or would be a contraindication to surgery or anesthesia.\n7. Subject who has smoked within the last 6 months.\n8. Subject who has alcohol or drug abuse within 12 months of screening.\n9. Subject unwilling or unable to comply with study requirements.","20 Years","65 Years",{"count":52,"type":22},10,[25],"Absolute Uterine Factor Infertility (AUFI) is due to congenital or surgical absence of a uterus or the presence of a nonfunctional uterus. Until 2014, the only option for women affected by Absolute Uterine Factor Infertility (AUFI) was adoption or surrogate motherhood. Uterine transplant is a new form of transplant to treat AUFI. The technique of uterus transplant was developed in Sweden with the transplantation of the uterus from a living donor to a woman affected by AUFI. Approximately 80 uterine transplantations have been performed, more than 50 of which have occurred within the past 3 years. To date, 34 children have been born from mothers who have received a living donor uterine transplant.\n\nThis is a prospective study to treat Absolute Uterine Factor Infertility (AUFI) through uterine transplantation utilizing a uterus from a living or deceased donor resulting in live birth. A total of 10 biologically female (XX Karyotype) subjects will receive a uterine transplant.",[56,57,28],"Mayer Rokitansky Kuster Hauser Syndrome","Absence of Uterus",[59,60,61,62,63],"Uterine Transplant","AUFI","Absolute Uterine Factor Infertility","Infertility","MRKH","2026-04-24",{"date":66,"type":33},"2026-04-29",{"date":68,"type":33},"2022-06-03",{"date":70,"type":22},"2030-12",{"name":72,"class":40},"John Goss",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100364565","deceased-uterine-transplant-in-absolute-uterine-infertility-auif-100364565","NCT04026893","Deceased Uterine Transplant in Absolute Uterine Infertility (AUIF)","Inclusion Criteria:\n\n* Evidence of AUFI diagnosed by BWH gynecologist\n* Ability to produce at least 6 euploid embryos for cryopreservation\n* BMI ≤ 30\n* GFR 60 or greater in any patient including those with a single kidney\n* PRA 20% or less\n* Deemed stable and capable of undergoing transplant by the transplant team to include psychiatry, social work, and transplant coordinator and study doctors to assure compliance with treatment\n* Evidence to be compliant with follow-up and immunosuppression\n* Partner willing to undergo psychological evaluation and receive immunizations as recommended\n* Stable home environment to support a child\n\nExclusion Criteria:\n\n* Active smoking, alcohol use or use of illicit drugs\n* Inability to follow a strict medication dosing schedule post-transplant and adhere to required follow-up appointments.\n* Any co-morbidities which would increase surgical risk, risk of pregnancy or the risk of taking anti-rejection medications as determined by the Maternal Fetal Specialist and Transplant Surgeon.\n* Active infection: HIV, Hepatitis B, Hepatitis C\n* Inadequate blood vessels to support the transplanted uterus.\n* Prior extensive abdominal or pelvic surgery\n* Presence of pelvic kidney\n* History of abnormal PAP\n* HPV related vulvar, vaginal or cervical dysplasia\n* Evidence of genital condylomata\n* History of PID\n* One or more living biological children",true,"40 Years",{"count":82,"type":22},250,[25],"Our study will explore the feasibility of initiating a deceased donor uterine transplant program in addition to the existing living donor IRB at BWH.\n\nUsing the template established by teams around the world, we will identify emotionally and socially stable females of reproductive age with intact ovaries who are unable to gestate a child due to congenital or acquired uterine factor infertility. After careful screening, participants will undergo egg harvest, in vitro fertilization, and embryo cryopreservation using standard methods. Women who successfully complete the fertilization of at least six euploid embryos will be eligible to be placed on the waitlist for a deceased donor uterus transplant. After a successful transplant and a period of observation to ensure normal menstrual cycle and graft viability (anticipate six months), embryo implantation will be undertaken.\n\nFollowing an embryo transfer, gestation will be carefully monitored by our high-risk pregnancy specialists. Medical research interventions include the surgical implantation of a uterus utilizing techniques by teams that have applied this approach successfully, close post-transplant follow up including immunosuppression therapy tailored to established standards during pregnancy minimizing fetal risks, and careful management of pregnancy. After childbearing is complete (at most two gestations), the donor uterus will be removed either during Cesarean or during an elective procedure. In addition, open ended interviews and surveys will be conducted to elicit ethical and psychosocial concerns arising from the experience of subjects and their families, health care providers, and the wider community. The investigator's intent is to monitor outcomes for transplant recipients as well as the live born infants for 30 days after removal of the transplanted uterus.\n\nIt is estimated that the time from screening to a potential live birth will be a minimum of 22 months, but likely between 24 - 36 months depending on organ availability.",[28],[60],"2026-04-22",{"date":89,"type":33},"2026-04-28",{"date":91,"type":22},"2026-05",{"date":93,"type":22},"2028-01",{"name":95,"class":40},"Brigham and Women's Hospital"]